About Us
Accelerating Cell & Gene Therapy with
OranssiBio (Shanghai) Co., Ltd.
Accelerating Cell & Gene Therapy with
Integrated CRO + CDMO Excellence
OranssiBio is a high-end research, development, and manufacturing service provider specializing in cell and gene therapies (CGT). We are committed to supporting global biopharmaceutical companies and research institutions with a fully integrated CRO + CDMO platform that spans the entire development lifecycle—from early-stage discovery and clinical trial material production to commercial-scale manufacturing.
Driven by the principles of quality, agility, and international compliance, OranssiBio is committed to accelerating the development of transformative CGT therapies — making advanced medicines accessible to more patients, and creating long-term value for society.
-
End-to-End Technology Platforms
Integrated platforms spanning plasmids, viral vectors, exosomes, mRNA-LNPs, and cell therapies — from concept to launch. -
High-Standard R&D and Manufacturing
From early development to GMP production, we ensure speed, scalability, and strict quality compliance. -
Global Regulatory Support
CMC-driven documentation and submission strategies tailored for FDA, EMA, NMPA, and global standards. -
Experienced Team Supporting Every Stage of the CGT Lifecycle
Cross-functional experts guiding you from discovery through clinical trials to commercial manufacturing.
Our Core Technology Platform
Powering innovation across the full CGT development and manufacturing lifecycle.
-
mRNA-LNP Platform
End-to-end development of mRNA therapeutics with precision lipid nanoparticle delivery.More -
Lentiviral Vector (LVV) Platform
Efficient gene transfer for cell-based therapies and durable in vivo expression.More -
Cell Therapy Platform
From patient to product — comprehensive support for autologous and allogeneic therapies.More -
Plasmid Platform
High-purity, GMP-grade plasmids — the foundation of gene therapy and vaccine platforms.More -
Exosome Platform
Next-gen delivery system enabling targeted, non-viral therapeutic payload transport.More -
Adeno-Associated Virus (AAV) Platform
Versatile vector system for safe, stable gene delivery in clinical and commercial applications.More
Integrated R&D and GMP Manufacturing Facility
-
6,500 m² GMP Manufacturing Suites
01 / 04Multiple GMP-compliant production lines with scalable capacity ranging from 0.1L to 400L, enabling flexible and phase-appropriate manufacturing.More -
3,000 m² R&D Laboratories
02 / 04Equipped with advanced analytical instruments and a proprietary "developability screening system" to support project evaluation and rapid progression.More -
Quality Management System
03 / 04Fully aligned with NMPA, FDA, EMA, and ICH regulatory standards to ensure global compliance and product quality.More -
Strategic location
04 / 04Located at Lingang, Shanghai’s Free-Trade Zone, serving as our central innovation and production hub.More
Why Choose OranssiBio?
-
Diversified CGT Platforms
Comprehensive technologies ensure flexibility and precision for complex, evolving cell and gene therapy projects. -
End-to-End Solutions
Seamless support from R&D to GMP manufacturing and regulatory submission, reducing time and complexity. -
Global Compliance
Fully aligned with FDA, EMA, and NMPA standards to ensure quality, safety, and global readiness. -
Operational Excellence
Top-tier materials and efficient logistics deliver 1.5–2× faster turnaround than industry average. -
Strategic Partnership
Led by experts and ideally located, we help advance your CGT programs toward real-world impact.
